Pfizer Inc. — 2012 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2012. This is an annual filing, not a quarterly report; the filing was signed February 28, 2013. Pfizer is a global biopharmaceutical company with human medicines, animal health and consumer healthcare businesses.
Business context and significant portfolio changes
- Pfizer reported five operating segments in 2012: Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; Animal Health; and Consumer Healthcare.
- Pfizer sold its Nutrition business to Nestlé on November 30, 2012, for $11.85 billion in cash.
- After year-end, Pfizer completed a Zoetis IPO in February 2013, selling approximately 19.8% of Zoetis in exchange for retirement of about $2.5 billion of Pfizer commercial paper. Pfizer retained control and continued to consolidate Zoetis; a further separation was under consideration, not assured.
Financial performance and material changes
| Metric | 2012 result | Comparison or context |
|---|---|---|
| Biopharmaceutical revenue | $51.2 billion | Down 11% from 2011. Loss of exclusivity and lower alliance revenue were major factors; foreign exchange reduced revenue by $1.3 billion, or 2%. |
| Animal Health revenue | Approximately $4.3 billion | Up 3%; operational growth of 6% was partly offset by a 3% foreign-exchange impact. |
| Consumer Healthcare revenue | $3.2 billion | Up 6%; operational growth of 8% was partly offset by a 2% foreign-exchange impact. Acquisitions contributed to operational growth. |
| Research and development expense | $7.9 billion | Compared with $9.1 billion in 2011 and $9.5 billion in 2010. |
| International revenue | $35.9 billion, or 61% of total revenue | The U.S. represented 39% of total revenue. International biopharmaceutical revenue declined 7%; U.S. biopharmaceutical revenue declined 17%. |
| Fourth-quarter share purchases | Approximately 136.0 million shares under announced plans; average price $24.96 | Approximately 137.1 million shares were purchased in total, including other transactions. A new $10 billion purchase plan became effective November 30, 2012. |
The supplied filing text refers investors to the incorporated 2012 Financial Report for consolidated revenue, net income, margins, cash flow, balance-sheet liquidity and debt figures; it does not provide clear values for those metrics. The filing describes Pfizer’s liquidity and capital resources as sufficient to meet foreseeable needs, supported by operating cash flow, financial assets, capital-market access and credit facilities.
Outlook, risks and unusual items
- The filing references 2013 financial guidance in the incorporated MD&A, but the guidance figures are not included in the supplied text.
- Management cited continuing revenue pressure from generic competition, patent expirations, pricing and reimbursement constraints, and foreign-exchange movements. Major 2012 exclusivity losses included Lipitor in most developed markets, Xalatan in major markets, Geodon in the U.S., and products including Caduet and Aromasin in certain markets.
- Pfizer reported 276 R&D projects at year-end, including 78 programs from Phase 1 through registration and 17 Phase 3 programs. Drug-development timing, approval and commercial success remain uncertain.
- Key risks include dependence on major products, patent challenges, pricing pressure, regulatory and product-safety requirements, litigation, currency movements, manufacturing or supply disruptions, and execution of restructuring, outsourcing and strategic transactions.
- The company disclosed a Corporate Integrity Agreement effective through December 31, 2014, and a subsidiary’s Deferred Prosecution Agreement with the DOJ, entered into in August 2012, with a term of approximately two years. Failure to comply could result in significant sanctions.
- Environmental spending in 2012 included $27 million of environment-related capital expenditures and $157 million of other environment-related expenses. Pfizer reported that disclosure controls were effective and no material change to internal control over financial reporting occurred in the latest quarter.
Important facts for investors to verify
- Consult the incorporated 2012 Financial Report for audited revenue, earnings, cash flow, margins, cash and debt, liquidity, and segment results; these figures are not clear in the supplied text.
- Review the exact 2013 guidance, assumptions and any subsequent revisions, as the guidance values are referenced but not reproduced here.
- Assess continuing patent-loss impacts and the commercial performance of growth products, including Lyrica, Prevnar 13 and Enbrel.
- Verify the financial and accounting effects of the Nutrition sale and Zoetis IPO, including Pfizer’s retained ownership, consolidation and any later separation plans.
- Review the status and potential financial exposure of material litigation, patent disputes, and compliance obligations under the CIA and DPA.